Drug Profile
Research programme:cc- AstraZeneca/FOB Synthesis
Alternative Names: Beta lactamase inhibitor/Carbapenem - AstraZeneca/FOB Synthesis; Beta lactamase inhibitor/FSI-1671 - AstraZeneca/FOB Synthesis; Beta lactamase inhibitor/FSI-1686 - AstraZeneca/FOB SynthesisLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator AstraZeneca; FOB Synthesis
- Class Carbapenems
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Gram-negative infections in United Kingdom (unspecified route)
- 27 Mar 2023 Discontinued - Preclinical for Gram-negative infections in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Gram-negative-infections in United Kingdom